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Abstract: The replication of human immunodeficiency virus type 1 (HIV-1) can be inhibited by noncytolytic CD8
+ T cell 
mediated suppression, an immune response that specifically targets HIV-1 gene expression. Clinical studies demonstrate 
that this immune response may play an important role in the host defense against HIV infection. In this study, we exam-
ined the distinct steps in viral gene expression for inhibition by noncytolytic CD8
+ T cells. A primary HIV-1 infection sys-
tem of CD4
+ enriched peripheral blood mononuclear cells was utilized to examine the HIV-1 life cycle as a relevant ex 
vivo system. Established CD8
+ T cell lines from two HIV
+ long-term nonprogressors were used to examine differences at 
the level of transcriptional initiation and elongation of the HIV genome. This infection system coupled with the results 
from real-time measurement of newly transcribed RNA transcripts determined that there was a significant decrease (5-8 
fold) in short intracellular viral RNA transcripts. These data strongly favor a role for the initiation of virus transcription in 
noncytolytic CD8
+ T cell mediated suppression. 
INTRODUCTION 
  The concept of non-cytolytic CD8
+ T cell mediated sup-
pression of HIV-1 unfolded in a seminal study by Levy’s 
group [1] that showed that CD8
+ T lymphocytes can inhibit 
HIV replication in a dose dependent manner. This activity 
does not require HLA histocompatibility [2], is distinct from 
the cytolytic activity of CD8
+ cells [3, 4] and is mediated by 
both cell contact and soluble molecules [5, 6]. The potency 
of noncytolytic CD8
+ T cell mediated activity from HIV in-
fected individuals in vitro has been shown to inversely corre-
late with disease progression [7, 8]. Several studies have 
confirmed that the CD8
+ T cell mediated activity positively 
correlates with a healthier clinical status [8-11]. In addition, 
a significant number of exposed uninfected individuals dem-
onstrate noncytolytic CD8
+ T cell mediated suppressive ac-
tivity [12, 13]. These clinical studies indicate that CD8
+ T 
cell mediated antiviral activity may play an important role in 
the host defense against HIV infection and thus have a great 
potential to be of use in vaccination strategies. These results 
will contribute to the goal of identifying the specific anti-
viral mechanisms, and viral and cellular components, that 
contribute to the control of viremia by noncytolytic CD8
+ T 
cell suppression. 
  The precise mechanism of CD8
+ T cell mediated noncy-
tolytic activity has not yet been fully delineated. The inhibi-
tion of virus replication can potentially take place at many 
different steps in the virus life cycle and therefore there is an 
array of molecules that may be the target of suppressive ac-
tivity. It is known that for the inhibition of viral entry of 
CCR5-tropic viruses, the -chemokines, MIP-1 , MIP-1 ,  
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and RANTES, can inhibit HIV replication by competitive 
inhibition of virus-coreceptor binding and downregulation of 
coreceptor cell surface expression [14-16]. The activities of 
these -chemokines appear to act at entry, and not HIV-1 
gene expression [17]. In addition, several well-characterized 
molecules have been tested for their ability to recapitulate 
this activity, but none can fully account for either the po-
tency of suppression or the breadth across CXCR4 and 
CCR5-tropic viral infections [6]. 
  In studies to examine the ability of CD8
+ T lymphocytes 
to act on viral gene expression, primary CD4
+ T lympho-
cytes were transfected with LTR driven reporter constructs 
to measure the effects of CD8
+ T cells on both basal and Tat 
mediated transcription of the HIV-1 LTR [18]. CD8
+ T cells 
from asymptomatic HIV-1 infected individuals could inhibit 
both basal and Tat mediated transcription and other work 
further substantiated these findings [19, 20]. Importantly, 
these affects on viral gene expression were also observed and 
confirmed using a primary lymphocyte culture in an ongoing 
cycle of viral replication where potent suppression of 
CXCR4-tropic viruses was shown not to involve entry or 
reverse transcription [21]. In addition, noncytolytic CD8
+ T 
cell mediated suppression does not target viral integration 
[22]. These studies, utilizing both reporter constructs and 
ongoing cycles of virus replication in primary lymphocytes, 
indicate that CD8
+ T lymphocyte suppression occurs some-
time between proviral integration and splicing. However, it 
was not clear at what stage of virus transcription the antiviral 
activity was targeting. Transcription of the viral genome 
involves a complex series of events that trigger the initiation 
of transcription by the assembly of factors at the viral pro-
moter. Once the transcript is initiated, another series of mo-
lecular interactions between the viral RNA and RNA binding 
proteins trigger elongation of the viral transcript. Previous 
studies examining the mechanism of action of noncytolytic 
CD8
+ T cells did not differentiate between initiation and 
elongation of virus transcription. Utilizing an approach that 2    The Open Virology Journal, 2007, Volume 1  Overman et al. 
distinguishes the molecular events occurring during HIV 
transcription, we demonstrate that noncytolytic CD8
+ T cell 
mediated suppression targets initiation of virus transcription, 
but does not significantly affect virus transcript elongation. 
In addition to providing a better understanding of the 
mechanism of CD8
+ antiviral activity, the results presented 
here could lead to the design of novel therapeutics that spe-
cifically inhibit the initiation of viral RNA transcripts. 
MATERIALS AND METHODS 
  Isolation and Preparation of Primary CD8
+ T lym-
phocytes. Peripheral blood mononuclear cells (PBMCs) 
were prepared from venous blood from a seronegative donor 
(nEW, HIV-1 Naïve CD8
+) by standard Ficoll-Hypaque den-
sity separation. PBMCs were activated for 3 days with anti-
CD3 (OKT3) and anti-CD28 antibodies at 37°C in a humidi-
fied CO2 incubator. CD8
+ T cells were isolated by negative 
selection with anti-CD4
+ antibody coated beads (Dynal, 
Lake Success, NY). CD8
+ cells from two asymptomatic 
long-term nonprogressors (LTNP) (JRHVS CD8
+ and HS 
HVS CD8
+) displaying potent suppressive activity for both 
X4 and R5 viruses were transformed with Herpesvirus 
saimiri (HVS) subgroup C strain 488-77 as previously de-
scribed [24] and characterized [21]. IRB approval was ob-
tained for all work with human specimens. 
 Pseudotyped  Virus  Production.  Pseudotyped viruses 
were produced by transfection of DNA into the human em-
bryonic kidney cell line, 293T, using FuGENE (Roche Inc.). 
The reporter virus DNA, pNL4-3.LUC.R
-E
- [obtained 
through the NIH AIDS Research and Reference Reagent 
Program from Dr. Nathaniel Landau [25, 26] was cotrans-
fected with the expression vector pNL4-3 env (a gift from 
Dr. T. Dragic). The virus-containing supernatants were har-
vested two days later, filtered through a 0.45m membrane 
and stored at -80° C in 20% v/v FBS. Viral tropism was 
tested in a human astroglioma cell line expressing either 
CD4
+ alone (U87.CD4), CD4
+ and CCR5 (U87.CD4.CCR5), 
or CD4
+ and CXCR4 (U87.CD4.CXCR4) all obtained 
through the NIH AIDS Research and Reference Reagent 
Program from Drs. HongKui Deng and Dan Littman [27]. 
U87 cells were grown in DMEM L-glutamine containing 1% 
Pen/Strep, 15% FBS, and selective agents (300 g/ml G418 
for CD4 alone cell lines, or 300 g/ml G418 plus 1 g/ml 
puromycin). In triplicate, U87 cells were seeded in a 96-well 
flat bottom plate at 7.5  10
3 cells/well and grown overnight 
at 37°C. The selective media was then removed and 100 ul 
of pseudotyped virus was added. Cells were infected for 2.5 
hours at 37°C. 100 ul of fresh media without selective agents 
was then added. 
  To assess viral tropism, at 72 hours post-infection the 
media was removed and cells gently washed with warm 
PBS. U87 cells were then lysed with 50 l of 1X Cell Cul-
ture Lysis Reagent (Promega, Madison, WI) and then frozen 
for >30 min at -80°C. 20 ul of each lysate was assayed with 
the Promega Luciferase Assay System on an EG&G 
(Berthhold) LB 96V luminometer and viral infection was 
measured in relative light units (RLU). 
 CD8
+ Suppression Assay. Suppression assays were per-
formed as previously described [21] with modifications as 
indicated. Peripheral blood mononuclear cells were prepared 
from freshly drawn blood from a pool of HIV
- donors and 
activated as described above. CD4
+ and CD8
+ enriched 
populations were obtained by negative selection with 
anti-CD8
+ or anti-CD4
+ antibody coated beads (Dynal, Lake 
Success, NY), respectively. CD4
+-enriched PBMC were in-
fected with 1 ml of pseudotyped virus per 1  10
6 CD4
+ cells 
in the presence of DEAE (20 g/ml) for 2.5 hours at 37°C. 
The cells were washed with PBS and resuspended at 4.5  
10
5cells per ml in AIM-V medium (Invitrogen, Carlsbad, 
CA) containing 20% v/v FBS and 40 U/ml IL-2. Previously 
enriched effector CD8
+ cells from LTNP and HIV
- donors 
were added at a 2:1 E:T ratio achieving a final concentration 
of 1.35  10
6 cells/ml. 200 l aliquots of the infectious cul-
tures, in triplicate, were transferred to a 96-well flat bottom 
microtiter plate and incubated at 37°C for 48 hrs. 
  At 48 hours post-infection, the cells used for RNA isola-
tion were pelleted and resuspended in a 1:5 v/v 
PBS:RNAlater (Ambion, Austin TX) solution, stored at 4°C 
overnight, then transferred to -20°C. To assess infection, 
cultures in the microtiter plate were washed with PBS at 48 
hours, lysed with 1X Cell Culture Lysis Reagent (Promega, 
Madison, WI) and then frozen for >30 min at -80°C. 20 ul of 
each lysate was assayed with the Promega Luciferase Assay 
System on an EG&G (Berthhold) LB 96V luminometer. Lu-
ciferase activity was measured in relative light units (RLU). 
  Viral RNA Analysis. Total RNA, including low molecu-
lar weight RNA, was isolated from the RNAlater-stored cell 
samples using the mirVana miRNA Isolation Kit (Ambion) 
according to manufacturer’s instruction. DNA was removed 
with a double DNase digest treatment using DNA-free (Am-
bion). The RNA samples were quantified using a spectro-
photometer and then electrophoresed on a 1% agarose gel to 
check the integrity. Real-time PCR with HIV specific prim-
ers (HIVshort-F and HIVshort-R) and host RPS9 specific 
primers (RPS9-F and RPS9-R1) was then performed to 
check for DNA contamination against a standard curve, de-
scribed below. The DNA-free RNA was then reverse-
transcribed (Thermoscript, Invitrogen) using reverse primers 
(Table 1) at 119 bp, ~2.9 kb, ~7.1 kb, and a luciferase region 
(9.7 kb) of the pNL4-3.LUC.R
-E
- genome (GenBank Acces-
sion number AF324493.1). 
Table 1.   
 
Primer  Sequence [5’to 3’]  5’ Position 
[bp] 
HIVshortF  CCTGGGAGCTCTCTGGCTAA 29 
HIVshortR  AACAGACGGGCACACACTACTTT 119 
3kb-F CAATGACATACAGAAATTAGTGGGAAA 2868 
3kb-R CTTTGGTTCCCCTAAGAAGTTTACAT  2958 
7kb-F TGGCAGGAAGTAGGAAAAGCA 7040 
7kb-R AGCAGCCCAGTAATATTTGATGAAC  7120 
Luc-F AGGTGGCTCCCGCTGAA  *9.6  kb 
Luc-R ACACCTGCGTCGAAGATGTTG  *9.7  kb 
RPS9-F GACGGGGAAGCGGAGCCAACA  **308 
RPS9-R1  GCTTCAGCTCTTGGTCGAGACGAG **418 
RPS9-R2  GCGAGCGTGGTGGATGGACTTG **5579 
*Primer locations are based on the luciferase gene sequence in Promega’s pGL-3 basic 
vector, forward primer at 1343 bp and reverse primer 1406 bp. The luciferase reporter 
gene is located in the nef gene of the HIV pNL4-3.LUC.R
-E
- genome at 8.3 kb. 
**Primer locations are based on Ensembl Gene ID: ENSG00000170889. Noncytolytic CD8
+ Suppression  The Open Virology Journal, 2007, Volume 1    3 
Table 2.  
 
Primer Position  mRNA 
NM_001013 
Position Genome 
ENSG00000170889 
RPS9-F 37  308 
RPS9-R1 147  418 
RPS9-R2 437  5579 
The RPS9 primers were designed based on GenBank Accession number U14971.1. 
The primer positions are listed in reference to the 5’ base relative to 
+1 transcrip-
tion/gene start. 
 
  Host gene RPS9 primer locations were at 418 and 5579 
bp (Ensembl Gene ID ENSG00000170889) (Tables 1,2). 
Transcript copy numbers for the above-mentioned locations 
were determined by real-time PCR on an ABI 7500 (Applied 
Biosystems, Foster City, CA) using SYBR Green PCR Mas-
ter Mix (Applied Biosystems). A melting curve analysis was 
performed on each run to insure amplicon specificity. A 
standard curve (plasmid copy range 10
2- 3  10
6) was gener-
ated using plasmid pNL4-3.LUC.R
-E
- with primers specific 
to the 119 bp region of interest. Acceptable slopes (M) for 
standard curves ranged from -3.1 to -3.6 (optimal slope, M= 
-3.3). All best fit lines demonstrated R
2 values > 0.98. Note: 
all primers were designed to yield amplicons of analogous 
size, approximately 100 bp, and were chosen for similar am-
plification efficiencies. The RNA extracted from each viral 
infection experiment was reverse transcribed in duplicate, 
and cDNA from each of the duplicates was used in two sepa-
rate real-time PCR experiments. The cDNA templates used 
in the real-time experiments were assayed in triplicate. 
RESULTS 
 Noncytolytic  CD8
+ T Cell Mediated Suppression Sys-
tem in CD4
+ T Lymphocytes. To examine the mechanism 
of noncytolytic CD8
+ T cell mediated suppression during the 
time of viral gene expression, we utilized a single cycle in-
fection assay in primary CD4
+ lymphocytes. Two established 
cell lines (JR-HVS CD8
+ and HS-HVS CD8
+) that mediate 
suppressive activity [21] were utilized to determine if viral 
RNA transcripts are inhibited at transcriptional initiation 
and/or elongation. In a manner analogous to the non-
transformed cells from which they were derived, the HVS-
transformed CD8 cells were shown to potently inhibit infec-
tion of both X4- and R5- dependent viruses [21]. Here we 
utilize the CD8
+ effectors and CD4
+ targets that were previ-
ously determined by our group to lack any demonstrable 
cytolytic [21] and allogeneic reactivities. This system allows 
the isolated study of the effects of noncytolytic CD8
+ sup-
pression on HIV replication in a system where we have pre-
viously measured the kinetics of HIV entry, reverse tran-
scription and early gene expression [21]. Fig. (1) shows the 
results of CD8
+ suppression assays using a CXCR4-tropic 
enveloped (NL4-3) pseudotyped virus. The CD8
+ effectors 
(JR HVS CD8
+ and HS HVS CD8
+) demonstrated a greater 
than one-log reduction in viral infection in contrast to the 
HIV-1 naïve CD8
+ cells (nEW CD8
+). We did note that there 
was more variation in the level of infection in the presence 
of the nEW CD8
+ cells, however the CD8
+ cells derived from 
the HIV
+ LTNP significantly suppressed HIV replication 
compared to nEW CD8
+ cells. 
 Noncytolytic  CD8
+ T Cell Mediated Suppression of 
HIV Gene Expression. To investigate the possible mecha-
nisms of suppression at transcriptional initiation and elonga-
tion, we utilized a system that combines reverse transcription 
of viral RNA transcripts with quantitative real time PCR 
(adapted from [28]). RNA was isolated from the CD8
+ sup-
pression assays shown in Fig. (1). Reverse transcription was 
utilized to construct cDNAs, and then real-time PCR was 
used to quantify viral RNA transcripts at various points in 
the HIV genome. Fig. (2) shows the different regions of the 
HIV genome that were reverse transcribed and then quanti-
fied using real-time PCR. HIV RNA transcript copy numbers 
were measured by quantitative real-time PCR at the follow-
ing positions along the HIV genome: 119 bp (HIVshort-R 
and HIVshort-F primers), 2,958 bp (3 kb-R and 3 kb-F), 
7,120 bp (7 kb-R and 7 kb-F), and 9,700 bp (Luc-R and Luc-
F). All short and longer transcripts were reversed transcribed 
from the RNA template using primer sets that resulted in 
amplicons of similar size, “short amplicon”, to accurately 
quantify and compare both long and short transcripts. Fig. 
(2) diagrams the RNA transcripts and PCR amplicons for 
both the short transcript that tests transcriptional initiation 
and also for one of the longer elongated transcripts (3 kb) as 
an example. Primers specific to a housekeeping gene, ribo-
somal protein (RPS9), were utilized at comparable positions 
on the gene as a control. 
 
Fig. (1). Noncytolytic CD8
+ T Cell Mediated Suppression of HIV 
NL4-3 Pseudotyped Virus Replication. CD4
+ T lymphocytes were 
infected with NL4-3 pseudotyped virus and exposed to CD8
+ T 
lymphocytes. (N=4) % Control Infection is the amount of infection 
relative to the control NL4-3 infected CD4
+ T-lymphoctyes. The 
cutoff for the upper limit for suppression was 10% infection, a 1-
log reduction, in the CD4
+ co-cultures with JR HVS CD8
+ and HS 
HVS CD8
+. * p = 0.023 for both JR and HS HVS CD8
+ compared 
to nEW CD8
+, Student t-Test. 
  Viral Suppression by CD8
+ Cells Occurs at Initiation. 
To define whether or not suppression occurred at transcrip-
tional initiation the initiation ratio of non-suppressed HIV 
short copy number to suppressed HIV short copy number 
[NSS/SS] was examined. The use of a single-cycle infection 4    The Open Virology Journal, 2007, Volume 1  Overman et al. 
prevented subsequent rounds of virus replication and al-
lowed the observance of a single viral replication cycle. At 
48 hours post infection, the initiation ratio demonstrated that 
the JR HVS CD8
+ and HS HVS CD8
+ cells executed signifi-
cant suppression at the initiation stage of viral transcription, 
on average 7.3 fold and 5.1 fold inhibition respectively (Fig. 
3). The HIV-naïve CD8
+ cells also exhibited inhibition, 3.7 
fold on average, albeit not to the strength of LTNP CD8
+ 
cells. Interestingly, this lower level of inhibition of initiation 
was consistent regardless of the level of infection in the 
presence of HIV-naïve CD8
+ cells. Both the JR HVS CD8
+ 
and HS HVS CD8
+ cells suppressed transcriptional initiation 
to a significantly higher level than the HIV-naïve CD8
+ cells 
(p < 0.001 for both comparisons, Student’s t-test). 
  The housekeeping gene, ribosomal protein S9 (RPS9), 
was measured to determine if the CD8
+ cells had a general 
effect on suppressing host cell transcription. From the same 
RNA isolates for every experiment, real-time PCR was used 
to quantify early transcription of the housekeeping gene. The 
data as shown in Fig. (3) illustrates there was no suppression 
of the housekeeping gene, RPS9 supporting the finding that 
CD8
+ T cell mediated suppression is unique to HIV tran-
scription. 
  Measurement of Transcripts that have completed 
Elongation and Splicing. Primers specific to near the 3 kb 
site of the HIV genome were designed to address the ques-
tion of whether noncytolytic CD8
+ T cell mediated suppres-
sion affects transcriptional elongation. An equation NSL/[SL 
x [NSS/SS]] was derived so that any contributing factors 
from transcriptional initiation could be included. Fig. (4) 
shows data from HIV short and 3 kb primers with the re-
sulted values of JR = 0.6, HS = 0.6, and EW = 0.8. The lack 
of significant effect (controlling for the suppressive effects at 
viral initiation) at approximately 3 kb from the start of viral 
transcription indicates that suppression of virus replication is 
likely limited to the initiation of transcription. In addition, 
RT-PCR was also used to quantify the late transcription 
products of the housekeeping gene, RPS9. There was no 
significant effect on RPS9 elongation. Because both RPS9 
transcriptional initiation and elongation are both near a 1:1 
ratio between non-suppressed and suppressed systems, this 
supports that there is no global effect of CD8
+ inhibition on 
general host cell gene expression. This supports previous 
data that non-cytolytic CD8
+ suppression is specific to HIV 
replication [18]. 
  The analysis of viral transcript elongation (including 
splicing) was extended further along the HIV genome to test 
for possible amplification of smaller effects downstream 
from those potentially present at shorter distances from the 
start of virus transcription. Fig. (5) shows the viral cDNA 
copy number measured at 3 kb, 7 kb, and 9.7 kb from the 
start of transcription for each of the four experimental condi-
tions (from the same set of samples examined in Fig. (4)). 
The fold difference between the suppressed and non-
suppressed viral cultures were determined by quantifying 
cDNA copy numbers using real-time PCR and then control-
ling for differences observed at transcriptional initiation. As 
was expected, the HIV short transcript (119 bp) was the most 
prominent in copy number in both non-suppressed (positive 
control) and suppressed systems. Based on the ratio 
NSS/NSL [non-suppressed short/ non-suppressed long viral 
RNA transcripts], which measures the progression from ini-
tiation [HIV short] to elongation (HIV long-3 kb), on aver-
age there are 3.8 times as many HIV short transcripts than 3 
kb transcripts in positive controls (N = 16). The addition of 
 
Fig. (2). Quantification of HIV RNA Transcripts from the HIV-1 Genome during Cellular Infection. Transcriptional initiation and elongation 
were examined using quantitative RT-PCR that measures RNA transcripts that reach a relatively short distance and also a much larger dis-
tance from the start of transcription. Reverse transcription was performed using primers near the LTR (“HIV short-R”) and within the pol 
gene (“3kb-R”). The short and long transcripts were quantified using primer sets of equivalent efficiency that amplified transcripts of similar 
length (“HIVshort-F and HIVshort-R” for the short cDNA transcript and “3kb-F and 3kb-R” for the long cDNA transcript). Strategy adapted 
from Sune et al. [28]. Noncytolytic CD8
+ Suppression  The Open Virology Journal, 2007, Volume 1    5 
JR HVS CD8
+ and HS HVS CD8
+ effector cells to infected 
CD4
+ T lymphocytes resulted in greater HIV short to 3 kb 
ratios, however, this was to a lesser degree, 2.9 and 2.1, re-
spectively (N = 16 and N = 12). There were fewer 3 kb cop-
ies than 7 kb or 9.7 kb copies in all samples tested and this 
was interpreted to be a consequence of the alternative splic-
ing of HIV-1 transcripts. 
 
Fig. (3). Reduction in Initiation of Transcription during Noncyto-
lytic CD8
+ T cell mediated Suppression of HIV Replication. Both 
JR-HVS and HS-HVS significantly suppressed viral transcription 
initiation more than the HIV naïve CD8
+ T cells (nEW CD8
+), p < 
0.001 for both comparisons, Student t-Test. The fold difference 
between the suppressed and nonsuppressed viral cultures were de-
termined by quantifying cDNA copy numbers from the short RNA 
transcripts using real time PCR. 
 
 
Fig. (4). Transcriptional Elongation/Splicing during Noncytolytic 
CD8 T cell mediated Suppression of HIV Replication. Using the 
derived equation [NSL/[SL x [NSS/SS]]], this figure illustrates the 
calculated elongation/splicing effects from non-cytolytic CD8
+ 
suppression as determined by the “fold difference between sup-
pressed and non-suppressed” viral cultures. By accounting for inhi-
bition at transcriptional initiation, ratio values of JR = 0.6, HS = 
0.6, EW = 0.8 indicate the likely absence of suppression at elonga-
tion and/or splicing (N = 16, N = 12, and N = 16, respectively). 
  Comparing the ratios of the HIV short transcript to either 
the 7 kb transcript or the 9.7 kb transcript, there was no dif-
ference between ratios for the positive controls and the CD8
+ 
T cell effectors. These data provide evidence that the inhibi-
tion of viral replication by noncytolytic CD8
+ suppression 
did not likely involve transcriptional elongation or splicing, 
but occurred predominately at the initiation of viral tran-
scription. 
 
Fig. (5). No significant Effects Past Initiation Regardless of Length 
of Viral RNA Transcript. The viral cDNA copy number was meas-
ured at four distances from the start of transcription for each of the 
four experimental conditions. When comparing copy number ratios, 
there is no significant difference (Student t-Test, p=0.331 to 
p=0.476) when comparing HIV short: 7 kb and HIV short: 9.7 kb 
transcript ratios in the positive controls vs suppressed systems (JR 
HVS CD8
+, HS HVS CD8
+) and nEW CD8
+. Regardless of the 
length of the transcript examined, there are no significant effects 
downstream of initiation. 
DISCUSSION 
  Here, it is reported that noncytolytic CD8
+ suppression of 
HIV replication is specific to the initiation phase of viral 
transcription. Previous studies demonstrated the involvement 
of HIV transcription [18, 19], but did not measure the dis-
tinct molecular steps of transcription: initiation and elonga-
tion. Expression of HIV-1 genes and inhibition by noncyto-
lytic CD8
+ suppression begins to occur by 17-25 hours after 
infection [21]. By choosing to evaluate suppression at the 
48-hour time point, basal and/or tat-mediated transcription 
occurred and were possible targets, while CD8
+ suppression 
was still in an optimal phase. 
  HIV-1 transcription is regulated by a complex interaction 
of cellular and viral proteins. Sequences within the HIV-1 
genome that are involved in viral gene transcription can be 
divided into the core promoter elements, the enhancer, the 
modulatory and negative regulatory elements and the tat re-
sponsive element (TAR). HIV transcription is primarily 
regulated by the viral promoter (5' long terminal repeat) 
which contains a canonical RNA polymerase II (RNAPII) 
TATA box, transcription factor binding sites and an initiator 
element [29]. Subsequent to the initiation of transcription, 
elongation occurs by competent RNAPII complexes. During 
transcriptional activation, the viral transactivator, Tat [30], 
binds to a viral RNA structure, the trans-activation response 
element (TAR) to increase the level of transcription by 
greater than 2-logs [31, 32]. Positive transcription elongation 
factor b (P-TEFb), Tat and TAR form a trimeric complex 
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kinase), phosphorylates the C-terminal heptapeptide repeate 
domain (CTD), of the largest subunit of RNAPII. Phos-
phorylation of CTD is thought to mediate the increase in 
transcript elongation. 
  Our work suggests that anti-viral CD8 T cells may sup-
press the transition from the initiation of viral transcripts to 
elongation of these same transcripts. The mechanisms and 
factors that could be involved include the alteration of CTD 
phosphorylation sites or modulation of Tat activities. Tat is 
primarily thought to be involved in transcriptional elonga-
tion, but several labs have presented evidence that Tat is 
likely to be involved in initiation by aiding in the assembly 
of the transcription complex (TC) (reviewed in [33]). Under-
standing whether anti-viral CD8
+ T cells act to modulate Tat 
activity to inhibit HIV replication will be important to con-
sider as potential pathways for the inhibition of viral tran-
scriptional initiation are explored. 
  Although the data generated here do not support CD8
+ 
suppressive activity at elongation and/or splicing, it is impor-
tant to note that this possibility cannot be fully eliminated. 
The role of C-terminal heptapeptide repeat domain (CTD) of 
RNAP II, CA150 and/or the Tat-P-TEFb complex (which 
includes cyclin T1) has yet to be fully investigated for their 
potential roles in inhibition of HIV. 
  There is some controversy as to the ability of HIV-naïve 
CD8
+ cells to suppress HIV infection. It is reported here that 
HIV-naïve CD8
+ cells inhibit transcriptional initiation of 
HIV, but the magnitude is less than that of the CD8
+ T lym-
phocytes derived from long-term nonprogressors. This is in 
agreement with the lower level of suppression of virus infec-
tion by these HIV-naïve CD8
+ T cells observed here. We can 
not exclude the possibility that the transformation of the 
CD8
+ lymphocytes may have contributed to the transcrip-
tional effects demonstrated here, although we consider it 
unlikely as previous work by our group demonstrated that 
the transformed cells recapitulated the phenotype of the pri-
mary cells from which they were derived [24]. 
  In the system presented here both soluble and contact 
mediated non-cytolytic CD8
+ cell suppression of viral repli-
cation are permissible. Previous studies have shown that 
CD8
+ T lymphocytes express and secrete soluble molecules 
capable of suppressing viral replication. The most notable of 
these molecules are the natural ligands for the CCR5 core-
ceptors, the -chemokines RANTES, MIP-1 and MIP-1, 
which do in fact inhibit viral replication by blocking viral 
entry. Since their discovery, however, several groups have 
shown that these soluble anti-viral factors cannot adequately 
explain the viral suppressive activity of CD8
+ T cells [34, 
35]. Here we report that the anti-viral suppression occurs 
during transcriptional initiation of the HIV viral life cycle 
(using X4-tropic virus) and this will further ongoing studies 
into the precise molecules involved in suppressing viral tran-
scriptional initiation. 
  Other than HIV-1, Hepatitis B virus is another virus de-
scribed as sensitive to non-cytolytic CD8
+ cell suppression 
activity [36]. The use of tat-mediated enhancement of viral 
transcription is a characteristic that differentiates HIV tran-
scription from Hepatitis B transcription. HIV and Hepatitis B 
are both inhibited by non-cytolytic CD8
+ T lymphocyte sup-
pression as both also use host cell transcriptional machinery 
for transcription of viral RNA. Considering that HIV utilizes 
a unique means of enhancing transcription through the HIV 
tat-protein and TAR-sequence (tat-activating region), and 
both HIV and Hepatitis B virus use host cell transcription 
machinery, non-cytolytic CD8
+ suppression could be medi-
ated by altering host cell transcription machinery that may 
act specifically in concert to target viral transcription. This 
idea is further supported by the complexity of cellular tran-
scription and the numerous possible targets for modification 
by host cell defense mechanisms. 
  As provided in this report, the use of an ex vivo system 
provides strong data showing that CD8
+ T cell suppression 
occurs at viral transcription. Future studies will focus on in 
vitro transcription and protein expression analysis to identify 
the molecular players. This discovery may provide some 
insight into how CD8
+ T cells from long-term nonprogres-
sors and exposed uninfected individuals may suppress HIV 
replication. Further uncovering of the exact mechanism 
around the initiation of viral transcription may lead to the 
development of novel therapeutics for HIV infection or in-
novative means to elicit this CD8
+ activity as part of a vac-
cine strategy. 
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